TRADING UPDATES: Poolbeg upsizes offer; Glenveagh backs outlook
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Price | 6.10p on 30-05-2025 | at 18:50:06
---|---|
Change | -0.05p -0.81% |
Buy | 6.20p |
Sell | 6.00p |
Buy / Sell FAB Shares |
Last Trade: | Buy 70,000.00 at 6.17p |
Day's Volume: | 1,096,831 |
Last Close: | 6.10p |
Open: | 6.15p |
ISIN: | GB00BDQZGK16 |
Day's Range | 6.10p - 6.40p |
52wk Range: | 2.90p - 10.50p |
Market Capitalisation: | £6m |
VWAP: | 6.305806p |
Shares in Issue: | 105m |
Sector: Health Care and Related Services
Listed In: FTSE AIM All-Share,
Fusion Antibodies (FAB) Latest Trades |
||||
Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
---|---|---|---|---|
Buy* | 70,000 | 6.17p | Ordinary |
16:22:48 - 30-May-25 |
Buy* | 41,935 | 6.1599p | Ordinary |
16:21:29 - 30-May-25 |
Sell* | 25,000 | 6.00p | Ordinary |
16:15:19 - 30-May-25 |
Sell* | 40,000 | 6.0263p | Ordinary |
16:12:54 - 30-May-25 |
Buy* | 2,469 | 6.44p | Ordinary |
16:06:18 - 30-May-25 |
Sell* | 100,000 | 6.14p | Ordinary |
16:00:45 - 30-May-25 |
Sell* | 40,000 | 6.0558p | Ordinary |
15:50:23 - 30-May-25 |
Sell* | 10,000 | 6.14p | Ordinary |
15:27:26 - 30-May-25 |
Buy* | 43,988 | 6.579p | Ordinary |
14:57:14 - 30-May-25 |
Buy* | 48,500 | 6.576p | Ordinary |
14:31:12 - 30-May-25 |
Fusion Antibodies (FAB) Regulatory News |
||
Date | Source | Headline |
---|---|---|
22nd May 2025 2:33 pm | RNS | Update on U.S. Patent for OptiMAL® |
8th May 2025 7:00 am | RNS-R | Investor presentation |
7th May 2025 7:00 am | RNS | Issue of shares to non-executive directors |
6th May 2025 10:53 am | RNS | Director/PDMR Shareholding |
6th May 2025 10:38 am | RNS | Holding(s) in Company |
6th May 2025 7:00 am | RNS | Trading update |
30th Apr 2025 5:00 pm | RNS | Total Voting Rights |
24th Apr 2025 7:00 am | RNS | Approval of grant funding |
11th Apr 2025 10:40 am | RNS | Holding(s) in Company |
10th Apr 2025 12:47 pm | RNS | Holding(s) in Company |